<DOC>
	<DOCNO>NCT02183389</DOCNO>
	<brief_summary>To investigate whether extent BI 1356 affect pharmacokinetic pharmacodynamic parameter warfarin</brief_summary>
	<brief_title>Bioavailability Warfarin After Coadministration With Multiple Doses BI 1356 Compared Bioavailability Warfarin Alone Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Linagliptin</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Healthy male accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test Age ≥ 18 Age ≤ 50 year BMI ≥ 18.5 BMI ≤ 29.9 kg/m2 ( Body Mass Index ) Signed date write informed consent prior admission study accordance good clinical practice ( GCP ) local legislation Homozygote wildtype carrier ( *1/*1 ) cytochrome P 450 ( CYP ) 2C9 Any find medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor Torsades de point ( TdP ) ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) Exclusion criterion specific study : Anemia screen Galactose intolerance Lactase deficiency Glucosegalactosemalabsorption</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>